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Frontotemporal dementia (FTD) is a clinically and
pathologically heterogeneous group of non-Alzheimer dementias
characterised collectively by relatively selective, progressive
atrophy involving the frontal or temporal lobes, or both.1-4Cases
of FTD have been described since the late 19th century, initially
most comprehensively by Arnold Pick, who lent his name to
the historical designation of the entire FTD spectrum as Pick’s
disease. Only in the past three decades, however, has the clinical
and pathological complexity of these diseases and their unique
status as examples of selective brain degeneration been fully
appreciated. FTD is substantially less common than Alzheimer’s
disease, with estimates of population prevalence ranging from
four to 15 per 100 000 before age 65 years in European and US
epidemiological studies.1 However, this disease group is of
disproportionate importance as a cause of young onset dementia
and all the attendant socioeconomic and human costs that entails.
Although onset is typically in the sixth decade of life, it may
begin as early as the third or as late as the ninth decade, and the
prevalence of FTD in older age groups has almost certainly been
underestimated.
Here we provide a general overview of FTD, emphasising
clinical aspects and highlighting recent progress and prospects.
Figure 1⇓ provides a schematic overview of FTD showingmajor
clinical and neuroanatomical syndromes and diseases, and the
relations between them.
What are the different syndromes of
frontotemporal dementia?
There are three main clinical syndromes of FTD, defined on the
basis of leading features at presentation. About half of cases
present with behavioural change (behavioural variant
frontotemporal dementia), and the remainder present with
language decline (primary progressive aphasia) characterised
either by impaired speech production (progressive non-fluent
aphasia) or by impaired word comprehension and semantic
memory (that is, memory for meaning) (semantic dementia).
There is variable overlap clinically between the syndromes and
atypical parkinsonism and motor neurone disease. New
consensus diagnostic criteria for FTD5 and the progressive
aphasias6 have recently been formulated, but they are likely to
be refined as more specific information about disease
pathophysiology arises and neuroimaging and other techniques
that can capture pathophysiological changes become available.
Methods for bedside assessment of behavioural variant
frontotemporal dementia and the progressive aphasias are
presented in the table⇓ and figure 2⇓, respectively. It is
particularly important for the non-specialist to have a workable
framework for suspecting FTD, as diagnosis, particularly early
in the course of the disease, is often challenging. In contrast to
Alzheimer’s disease (the most common cause of dementia in
later life), FTD often presents in middle life, and memory and
navigational skills and other aspects of general intellect are often
well maintained initially. Behavioural or personality changes
may at first suggest a primary psychiatric disorder, particularly
if accompanied by psychotic features: clues that such features
are harbingers of FTD may include a lack of any prior
psychiatric history and emergence of certain specific symptoms
such as changes in eating behaviour or social faux pas. Isolated
language disturbances may also be misattributed to
psychological factors: early features of primary progressive
aphasia may include stumbling over longer words, emergence
(or re-emergence) of a stutter, grammatical slips or problems
using more specialised vocabulary associated with a profession
or hobby (for example, a keen gardener may lose the names for
flowers). Brain imaging (ideally with magnetic resonance
imaging) is mandatory in all suspected cases of FTD to rule out
mimic conditions such as brain tumours and to demonstrate
signature atrophy patterns that may confirm the diagnosis or
identify a non-degenerative “phenocopy.”7
We now discuss symptoms and clinical findings in the major
syndromes of FTD.
Behavioural variant frontotemporal dementia
This syndrome is characterised by progressive decline in
interpersonal and executive skills, with altered emotional
responsivity and emergence of a variety of abnormal behaviours
including apathy, disinhibition, obsessions, rituals, and
stereotypies (see table 1⇓).5 Behavioural variant FTD can
develop indolently, and early detection may depend on subtle
changes of social circumstances (such as switching jobs or
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Summary points
Frontotemporal dementia refers to a diverse group of conditions that collectively are a major cause of young onset dementia
Frontotemporal dementia produces selective brain atrophy involving the frontal and temporal lobes, requiring brain magnetic resonance
imaging for accurate diagnosis
Clinically, these diseases present chiefly as progressive aphasia or as disintegration of personality and behaviour that may bemisdiagnosed
as a psychiatric disorder
Up to around a quarter of cases arise from dominant mutations in one of three major causative genes
Frontotemporal dementia is commonly associated with other neurological impairment, in particular parkinsonism or motor neurone
disease
Treatment remains supportive, but patients and families need extensive counselling, future planning, and involvement of social and
mental health services
Sources and selection criteria
We examined recent literature on frontotemporal dementia, targeting full text English language studies published since 1990. We selected
articles on the basis of our personal knowledge and searches of the Medline database using the terms “frontotemporal dementia,”
“frontotemporal lobar degeneration,” “progressive nonfluent aphasia,” “semantic dementia,” and “logopenic aphasia,” and each of these
terms in conjunction with “diagnosis,” “treatment,” and “therapy.” The final selection of references was based on our judgment of relevance,
completeness, and compatibility with recent clinical, pathological, and genetic criteria.
partners), idiosyncratic lapses of taste or social awareness,
reduced libido, altered dietary or musical preferences, or more
childlike amusements. The relevant history has to be actively
sought by speaking with the caregiver alone; forgetfulness may
be volunteered as the presenting complaint, even though careful
questioning often suggests that the patient’s memory for
everyday events is well maintained. To probe for a history of
subtle behavioural change, we find it useful to ask the caregiver
if the patient has said or done anything in public that has
embarrassed other parties; if they seem less warm or affectionate
(especially toward grandchildren or pets); if their food
preferences have altered or narrowed or their table manners
have declined; if they seem more concerned with timekeeping
or tend to watch the clock; if there has been a change in their
sense of humour; or if they have developed new hobbies or
interests, especially with a religious or spiritual bent, and if
these are pursued obsessively.
During the consultation, patients’ spontaneous behaviours and
interactions with others are often more revealing than formal
neuropsychological testing: they may be impulsive or
distractible, inert or impassive, disinhibited (picking up items
unbidden from the examiner’s desk) or socially unaware (fixing
the examiner with a baleful stare). Cognitive assessment may
reveal deficits of executive functions requiring formulation of
a strategy, response inhibition, or abstraction: widely used
bedside executive tests include verbal fluency (list as many
words as possible in one minute, according to a nominated
criterion such as starting letter or semantic category), cognitive
estimates (make an educated guess about some arbitrary property
or quantity, for example, the number of lions in Belgium), and
proverb interpretation (summarise the abstract meaning behind
a familiar saying). Memory and posterior cortical functions are
often relatively spared, and indeed performance on standard
psychometric tests is sometimes remarkably preserved. There
is often a paucity of associated neurological signs, though
primitive reflexes (forced grasping or rooting) may emerge later
in the course, and behavioural variant FTD may be associated
with extrapyramidal or motor neurone signs as part of an overlap
syndrome.
Magnetic resonance imaging (MRI) findings in behavioural
variant FTD are variable: there is often frontal and anterior
temporal lobe atrophy (fig 1⇓), which tends to be asymmetric
between hemispheres and to spare more posterior cortical areas,
but the degree and extent of atrophy vary widely among
individuals. Altered white matter signal may be prominent,
usually in close proximity to areas of cortical atrophy, where it
may reflect gliosis. Involvement of orbitofrontal cortex is an
early harbinger of FTD8 but can be difficult to detect reliably,
and brain atrophy may be detected only on serial studies.
Metabolic brain imaging with single photon emission computed
tomography (SPECT) or fluorodeoxyglucose positron emission
tomography (FDG-PET) may be diagnostically useful in
detecting regional dysfunction when structural imaging seems
normal.9 Phenocopies of behavioural variant FTD with normal
structural and metabolic brain imaging and lack of clear
progression on serial neuropsychological assessment are
increasingly recognised7: the nature of the underlying disease
in these cases remains unclear.
Semantic dementia
This is a highly characteristic syndrome led by progressive
breakdown of semanticmemory—thememory system that stores
knowledge about objects and concepts based on the individual’s
accumulated experience of the world. Typically, semantic
dementia initially affects the highly elaborate brain knowledge
system that mediates vocabulary—that is, knowledge of the
meaning of words.10 Asking the meaning of familiar words,
encountered, for example, in a menu (“What is asparagus?”),
is pathognomonic of semantic dementia. Patients commonly
present with fluent (or even garrulous) but empty,
circumlocutory speech with early prominent difficulty retrieving
names, use of less precise terms, and impaired comprehension
of word meanings, accounting for the “semantic variant of
progressive aphasia” in the current classification (see fig 2⇓).6
Early in the course of the disease, the semantic deficit may be
well compensated and may emerge only on testing more
specialised knowledge previously at the patient’s command. A
more pervasive semantic impairment also affecting visual
information (impaired recognition of familiar faces
(prosopagnosia) or of visual objects (visual agnosia)) and other
non-verbal domains such as odours and flavours generally
develops later in the disease course, as do behavioural
disturbances broadly similar to those in behavioural variant
FTD.10 The general neurological examination is usually normal.
Semantic dementia shows a highly consistent and characteristic
neuroanatomical (MRI) profile with selective, asymmetric
anteroinferior temporal lobe cortical atrophy and
hypometabolism (fig 1⇓),11 the gyral glia at the temporal poles
often persisting only as a residual “knife blade” skeleton.
Atrophy is predominantly left sided but may be right sided in
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cases led by non-verbal semantic deficits,12with spread between
the cerebral hemispheres and into more posterior temporal and
inferior frontal cortices over time.
Progressive non-fluent aphasia
This syndrome is led by a progressive breakdown in language
output with effortful non-fluent speech. Several more or less
distinct neurolinguistic syndromes are subsumed under the
general category of progressive non-fluent aphasia.13 In some
patients, speech sound (phonemic) or articulatory (phonetic,
speech apraxic) errors are the dominant feature; whereas in
others the syndrome is dominated by expressive agrammatism
with terse telegraphic phrases (see fig 2⇓). These features
commonly coexist as the disease evolves. Apraxia of other
orofacial movements or swallowing often accompanies speech
apraxia and is tested by asking the patient to yawn or cough,
which they are unable to do to command, although they can as
a reflex. Impaired sentence comprehension can generally be
demonstrated on neuropsychological assessment, and literacy
skills become affected in most cases. Progressive non-fluent
aphasia may herald the onset of a neurological overlap syndrome
with atypical parkinsonism or less commonly motor neurone
features.
Brain atrophy and hypometabolism in progressive non-fluent
aphasia often affects perisylvian cortices in the dominant
hemisphere mediating speech production (fig 1⇓).14 However,
the profile of atrophy varies widely in extent and severity
between patients.
A third clinical syndrome of progressive aphasia, logopenic
(Greek “few words”) aphasia, presents with hesitant but
grammatically correct speech marred by word-finding pauses,
anomia, and impaired phonological working memory
manifesting as disproportionate difficulty repeating spoken
phrases versus single words (fig 2⇓). Most cases will have
underlying Alzheimer pathology,6 and more widespread
cognitive deficits similar to those accompanying other
Alzheimer phenotypes emerge later in the disease course. Brain
MRI often shows predominantly left sided temporoparietal
atrophy,14 though with substantial individual variation that
overlaps with the neuroanatomical profile of progressive
non-fluent aphasia.
Overlap syndromes
The FTD spectrum overlaps with the syndromes of progressive
supranuclear palsy, corticobasal syndrome, and FTDwith motor
neurone disease. The progressive supranuclear palsy syndrome
is characterised by impairment of vertical gaze, early postural
instability with falls, and frontal behavioural changes with
marked cognitive slowing (fronto-subcortical).15 16 Features of
corticobasal syndrome include asymmetric apraxia accompanied
by rigidity and myoclonus and classically non-volitional or
“alien” actions of the affected limb.15 The phenotype may
include prominent behavioural or language deficits.16
In the syndrome of FTD with motor neurone disease,
behavioural or language dysfunctionmay evolve in tandemwith
motor neurone disease. However, all patients with FTD
presentations should be assessed for the appearance of motor
neurone signs (often initially deltoid or triceps fasciculations),
while cognitive and behavioural involvement in patients
presenting with motor neurone disease is almost certainly
under-recognised. Neurophysiological studies may confirm
widespread denervation, but for uncertain reasons this is often
normal earlier in the course of FTDwith motor neurone disease.
As the genetic and pathological spectrum of FTD has become
better defined, it has been recognised that molecular pathologies
in this spectrum can alternatively present with clinical
syndromes more typical of other neurodegenerative diseases,
in particular Alzheimer’s disease.
How is frontotemporal dementia
distinguished from other diseases?
FTD syndromes must be distinguished from non-degenerative
processes that present with prominent behavioural, executive,
and language disturbance (such as primary psychiatric illness,
tumours, and cerebrovascular disease) and from other
neurodegenerative diseases (notably atypical variants of
Alzheimer’s disease).6 Although cerebrovascular changes are
common on brain MRI in older patients, primary progressive
aphasia can usually be distinguished from vascular aphasic
syndromes based on a history of insidious deterioration; the
distinction between behavioural variant FTD and
cerebrovascular behavioural syndromes is more challenging,
but may rest on the relative extent of vascular and regional
atrophic changes. Neuropsychological assessment is valuable
in substantiating the bedside impression—particularly for
detecting “subclinical” involvement of cognitive domains that
help to define the phenotype, for quantifying impairment in
domains that may be difficult to assess at the bedside (such as
semantic memory or sentence comprehension), and for tracking
deterioration over time. OnMRI, lack of the focal brain atrophy
profiles that characterise FTD or prominent white matter change
are important clues to an alternative disease.
Because of the wide phenotypic variation within the spectra of
Alzheimer’s disease and FTD, it can be difficult to differentiate
FTD from Alzheimer’s disease in an individual case based on
clinical and imaging features.17Clinical “red flags” that a patient
has FTD rather thanAlzheimer’s disease include early prominent
behavioural features, especially if the social façade breaks down
or insight is lost and if episodic and topographical memory
remain relatively intact. Profiling of neurodegeneration marker
proteins in cerebrospinal fluid is increasingly used in clinical
diagnosis: a raised ratio of total tau protein to beta amyloid1 42
peptide sensitively predicts Alzheimer’s pathology,18 and
incorporation of other amyloid and phosphorylated tau species
may further enhance diagnosis.19 Cerebrospinal fluid profiling
is likely in future to be supplemented by molecular
neuroimaging (for example, for amyloid) and by more
specialised structural MRI analysis tools. One large study found
that cerebrospinal fluid profiling and analysis of brainMRI data
with a specialised classifier algorithm could distinguish
pathologically proven FTD from Alzheimer’s disease with
around 75% accuracy.20 However, such techniques remain to
be widely translated beyond specialist centres.
What causes frontotemporal dementia?
The common pathological theme underpinning FTD is tissue
deposition of abnormally aggregated proteins (see fig 1⇓).1 2
Three major pathogenic proteins have been implicated in FTD:
cases with cellular inclusions containing predominantly
phosphorylated tau or transactive response DNA-binding protein
43 (TDP-43) are approximately equally represented in autopsy
series, while a substantial minority have inclusions containing
fused in sarcoma (FUS) protein. These have been further
classified into distinct subtypes, with only a dwindling minority
of FTD cases having inclusions in which the pathogenic protein
is unclear (see fig 1⇓).
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FTD has a substantial genetic component, with an autosomal
dominant inheritance pattern or identifiable disease-causing
mutations in around 10-20% of cases across large published
series,3 4 and some family history in a higher proportion. Most
familial cases of FTD have mutations in the microtubule
associated protein tau (MAPT) or progranulin (GRN) genes or
the recently identified hexanucleotide repeat expansion in the
C9ORF72 gene (see fig 1⇓).4 Less often, mutations in the gene
encoding valosin containing protein (VCP) cause FTD in
association with inclusion body myositis and Paget’s disease
of bone.4
Can we predict molecular pathologies in
frontotemporal dementia?
Despite recent histopathological and genetic advances,2 4
accurate prediction of underlying molecular pathologies within
the FTD spectrum remains problematic (fig 1⇓). This has
important implications for targeting future disease modifying
therapies and, more immediately, for counselling of patients
and family members. While phenotypic variation and overlap
are substantial, certain clinico-anatomical profiles are
consistently associated with particular molecular pathologies
(see fig 1⇓).21 These include FTD with motor neurone disease
associated with TDP-43 pathology; the semantic dementia
syndrome and focal, asymmetric temporal lobe atrophy with
TDP-43 type C pathology; behavioural variant FTD of very
young onset and prominent caudate atrophywith FUS pathology;
and the progressive supranuclear palsy syndromewith a specific
tauopathy. Non-fluent speech breakdown and the development
of parkinsonism are more commonly associated with tau than
non-tau pathologies. The heritability of particular FTD
syndromes varies substantially3: semantic dementia is generally
sporadic, whereas behavioural variant FTD and corticobasal
syndrome are highly genetically as well as pathologically
heterogeneous. Useful neuroanatomical associations whichmay
help guide genetic testing include relatively symmetric
anteromesial temporal lobe atrophy with MAPT mutations and
striking asymmetric hemispheric atrophy with GRN mutations
(see fig 1⇓).4
What is the prognosis in frontotemporal
dementia?
The clinical course of all FTD syndromes is steadily progressive,
with declining function in everyday life and accumulation of
social, cognitive, and neurological disabilities leading to
complete dependency requiring institutional care. However,
survival duration based on meta-analyses is highly variable
across the FTD spectrum22: the most aggressive course is
associated with FTD with motor neurone disease, leading to
death typically within three to five years of symptom onset,
whereas a substantial proportion of patients (particularly those
with semantic dementia) survive for well over a decade. There
tends to be convergence of syndromes over time,23 with
emergence of non-cognitive neurological features inmany cases,
and the precise clinical trajectory is difficult to predict in
individual cases. Wandering and intrusive behaviours, apathy,
incontinence, mutism, and dysphagia are common issues toward
the end of life and important sources of caregiver distress. The
burden placed on those who care for patients with FTD is great,
even in comparison with other neurodegenerative diseases.24
What are the management options in
frontotemporal dementia?
There are no therapies currently shown to alter the evolution of
any of the diseases in the FTD spectrum. Management is
therefore directed to controlling symptoms and otherwise
helping patients and their caregivers cope with the impact of
their illness, including engagement of community mental health,
social services, day centres, and other support networks. Patients
and families need clear and specific advice as they face a future
of increasing dependency, often including occupational and
financial planning. This is particularly urgent where (as is often
the case in FTD) patients lack insight into the true extent of
their difficulties. Early, accurate diagnosis and mobilisation of
appropriate support services at present offer the best prospect
of effective management for patients with FTD.
Non-pharmacological management strategies are based largely
on anecdote and clinical experience rather than controlled
evidence.24 Safety and risk management are important
considerations that may entail environmental or other
modifications affecting diverse aspects of the patient’s daily
life: depending on the disease stage, these may include
occupational and social activities, children or other vulnerable
dependents, driving, swallowing, and mobility. Decisions about
safety and competence may be particularly challenging earlier
in the course of behavioural variant FTD, but the desire to
preserve autonomy must be weighed against the potential for
occupational, financial, social, or forensic hazards.
Simple interventions (puzzles, music, and other structured
activities, controlled access to food and drink) may help govern
troublesome behaviours and contribute to a stable routine.Motor
and gait symptoms should be anticipated as the disease evolves.
Speech and language therapy can provide simple communication
aids, as well as assessment of swallowing and advice on dietary
modification, and mobility and continence aids often become
necessary later in the course. Programmed respite, counselling,
and psychological support for caregivers should not be
overlooked: in contrast to other neurodegenerative diseases
(notably Alzheimer’s disease), FTD tends to strike early at the
core of personal identity, and the sense of living with a stranger
is often a source of profound distress for families and caregivers.
Genetic counselling of at-risk family members adds a further
challenge and should always be undertaken in collaboration
with a clinical genetics service.
Options for pharmacotherapy are limited. The available evidence
is derived largely from small, open label studies or case reports.24
Open label studies have shown no clear symptomatic benefit
for cholinesterase inhibitors or memantine,24 and one
randomised, double blind trial of memantine in behavioural
variant FTD was also negative25; these agents may aggravate
behavioural disturbance. Small, double blind, controlled trials
have provided some evidence for modest improvement of
behavioural symptoms with trazodone26 though not paroxetine.27
Clinical experience suggests that selective serotonin reuptake
inhibitors may be useful in modulating intrusive or compulsive
behaviours in some patients. Neuroleptic drugs are potentially
associated with substantial risk of extrapyramidal and cognitive
side effects,28 but adequate controlled studies to estimate the
risk-benefit balance of these agents in FTD are lacking.24 For
the moment, it seems pragmatic to reserve use of neuroleptics
to newer generation agents at low doses when required for
agitation that threatens the patient’s wellbeing and cannot be
managed by other means. Limited data from a single randomised
controlled trial suggest a transient benefit of intranasal oxytocin
on emotion processing in behavioural variant FTD.29
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What are the future prospects for therapy?
Translation of recent molecular progress into targeted therapies
of the proteinopathies underpinning FTD seems likely to depend
on earlier and more accurate disease detection and tracking as
much as on animal and cellular models for drug development.
More information is required about the clinical course of FTD
syndromes, the early and presymptomatic manifestations of
disease, and functional landmarks that subsequently affect
patients’ daily lives. There is a particularly urgent need for new
in vivo markers of specific pathological proteins (for example,
tau binding ligands) and novel metrics of brain network
disintegration and pathophysiology and complex behavioural
symptoms in order to capitalise on recent insights from systems
neuroscience.
Genetic forms of FTDmay be particularly attractive candidates
for targeted therapies, as there is potential for presymptomatic
disease detection. One promising example is progranulin, which
can be measured in plasma and for which there is considerable
information concerning disease biology.30
Collaboration among specialist centres, such as the Genetic
Frontotemporal Dementia Initiative,31 with access to well
characterised cohorts of patients with FTD will be essential to
mount large scale trials of rationally targeted therapies that may
finally allow us to treat these devastating diseases.
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Questions for further research
• Can tissue pathology be predicted reliably in frontotemporal dementia (FTD)? Identification of clinical, brain imaging, laboratory, and
other markers of underlying pathology may allow targeting of disease modifying treatments in FTD
• What are the earliest features of disease onset in FTD? Identification of early—ideally, presymptomatic—markers of disease onset
may allow intervention while structural brain damage is minimal, especially in genetic cases
• How can the evolution of FTD be tracked reliably? More detailed information about the clinical course of FTD would allow treatments
to be evaluated and monitored
• What are the markers of prognosis and survival in individual patients with FTD? Identification of reliable prognostic markers would
allow more specific advice to be given to patients and caregivers
Tips for non-specialists
• In contrast to Alzheimer’s disease (the most common cause of dementia in later life), frontotemporal dementia (FTD) often presents
in middle life, and memory and navigational skills are often well maintained initially
• Behavioural or personality change first developing in later life may signal the onset of FTD rather than a primary psychiatric disorder,
even if there are psychotic features, and particularly if heralded by changes in eating behaviour or social faux pas
• Problems articulating longer words, emergence of a stutter, grammatical slips, searching for words, or loss of comprehension of words
(asking the meaning of words) may herald the onset of progressive aphasia
• Brain imaging (ideally with MRI) is mandatory in all suspected cases of FTD to rule out mimics such as brain tumours and to confirm
the diagnosis
Additional educational resources
• Association for Frontotemporal Degeneration (www.theaftd.org/about/our-mission)—Free resource
• e-Brain e-learning initiative (www.ebrainjnc.com/)—Interactive online learning for professionals in the neurosciences. Registration
required
Resources for patients and caregivers
• Alzheimer’s Society frontotemporal dementia fact sheet (www.alzheimers.org.uk/site/scripts/documents_info.php?
documentID=167)—Freely available factsheet “What is fronto-temporal dementia (including Pick’s disease)?”
• Frontotemporal Dementia Support Group (www.ftdsg.org/)—Free resource including web links to many other useful lay resources
• Support groups based at the Dementia Research Centre (www.ucl.ac.uk/drc/support-groups)—Free resource from Dementia Research
Centre, UCL Institute of Neurology, London
Table
Table 1| Bedside assessment of behavioural variant frontotemporal dementia (adapted from Rascovsky et al5)
Examples†Main behavioural features and subtypes*
Disinhibition:
Inappropriately approaching, touching, or kissing strangers, verbal or physical aggression,
fatuity, staring
Socially inappropriate behaviour
Inappropriate laughter, jokes, or opinions that may be offensive to others, faux pas, lack of
etiquette, altered dress sense
Loss of manners or decorum
Reckless driving, new onset gambling, buying or selling objects without regard for consequencesImpulsive, rash, or careless actions
Apathy and inertia:
Lacking initiative, ceasing to engage in former activities or hobbies, poor personal hygieneApathy
Needs prompting to initiate or continue routine activities, less likely to initiate or sustain a
conversation
Inertia
Environmental dependency, utilisation behaviours (such as handling or using items or reading
signs aloud when not required or appropriate to social context)
Reduced autonomy
Loss of sympathy and empathy:
Making hurtful comments or disregarding other people’s pain or distress, less warmth or interest
toward others (such as grandchildren, pets), hypoemotionality, failure to appreciate ambiguous
social signals (such as sarcasm)
Diminished response to other people’s needs and feelings
Decrease in social engagement, emotional detachment, distant from friends and relatives,
reduced libido, altered sense of humour
Diminished social interest, interrelatedness, or personal warmth
Perseverative, stereotyped, and compulsive or ritualistic behaviour:
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(continued)
Examples†Main behavioural features and subtypes*
Tapping, clapping, rubbing, scratching, picking at self, humming, rockingSimple repetitive movements
Counting and cleaning rituals, collecting or hoarding, checking, ordering objects, walking fixed
routes, clock watching, new obsessional interests or preoccupations (such as religiosity,
musicophilia)
Complex, compulsive, or ritualistic behaviours
Habitual repetition of words, phrases, or themesStereotypy of speech
Hyperorality and dietary changes:
Carbohydrate cravings (particularly sweets), food fadsAltered food preferences
Consuming excessive amounts of food, gluttony, rapid, messy eating, overfilling mouth,
compulsive use of alcohol or smoking
Binge eating, increased consumption of alcohol or cigarettes
Pica, features of Kluver-Bucy syndromeOral exploration or consumption of inedible objects
Unaware of or unconcerned by difficultiesLoss of insight
Others:
Hallucinations (especially somatic or visual), delusions (especially somatic or paranoid)‡Psychotic features‡
Hypochondriasis, heightened distress with innocuous stimuli, lack of distress in response to
painful stimuli
Altered sensitivity to pain
Dressing inappropriate to climateAltered temperature sensibility
*Within the broad phenotype of behavioural variant frontotemporal dementia; clinical features in individual patients are highly variable.
†Early features are often loss of warmth and empathy, social faux pas, and altered eating behaviour or food preferences.
‡Especially in association with expansions in the C9ORF72 gene.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;347:f4827 doi: 10.1136/bmj.f4827 (Published 6 August 2013) Page 7 of 9
CLINICAL REVIEW
Figures
Fig 1 Molecular pathologies and phenotypic correlations in frontotemporal dementia. The schematic shows major genes
causing frontotemporal dementia, histopathological substrates, and clinical phenotypes. Neuroanatomical profiles are shown
as coronal magnetic resonance imaging sections (left hemisphere displayed on the right) abutting the corresponding
pathological substrates, with regions of predominant regional atrophy demarcated by white rectangles. Genetic bases for
pathological substrates and phenotypic associations of tissue pathologies are shown as intersecting (for example, mutations
in the progranulin gene (GRN) are associated with TDP-43 type A (TDP-A) pathology, which may be associated with clinical
syndromes of behavioural variant frontotemporal dementia (bvFTD), progressive non-fluent aphasia (PNFA), corticobasal
syndrome (CBS), and frontotemporal dementia with motor neurone disease (FTD-MND)). Group functional neuroimaging
studies have demonstrated involvement of intrinsic, large scale brain networks in FTD syndromes: a medial paralimbic
network (including anterior cingulate, orbital frontal, and frontoinsular cortices) in bvFTD32; an anterior temporal and inferior
frontal network in semantic dementia32 33; and dorsally directed dominant hemisphere language networks in PNFA.32 33
However, the network correlates of particular molecular pathologies are less well established.34 This scheme arranges
diseases according to whether they produce damage that is relatively more restricted to anterior (toward left of figure) areas
or extends posteriorly (toward right of figure) within each cerebral hemisphere; whether damage within a hemisphere is
more focally restricted to the temporal lobes (toward bottom of figure) or more distributed (toward top of figure); and according
to the degree of asymmetry of involvement between the two hemispheres (more asymmetrical diseases shown more
centrally)21 34
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Fig 2 Bedside clinical assessment of the progressive aphasias: a simple algorithm (informed by current consensus criteria
for progressive aphasia6) for syndromic diagnosis of patients presenting with progressive language decline. The clinical
syndromic diagnosis should be supplemented by neuropsychological assessment, brain magnetic resonance imaging, and
ancillary investigations including cerebrospinal fluid examination (see text)
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